Hemic and Lymphatic Diseases
Hemic and Lymphatic Diseases
Explore linked clinical trials. Standard reference: MESH:M00100727,158 results · Page 1 of 287
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| The Safety of Simplified Tranexamic Acid Regimen | Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, hematologic disorder, hemorrhagic disease, injury, vascular disorder, vascular hemostatic disease | Recruiting | Phase 4 | 2026-10-09 | NCT07869537 | |
| BLinatumomab and iNKT in Relapsed B-Cell ALL | B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Disease Attributes, Disease Progression, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Tumor Virus Infections, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Not yet recruiting | Phase 1 | 2026-10-09 | NCT07869368 | |
| NAC for Hematopoietic Recovery in Low/Intermediate-Risk AML After CR: A Randomized Controlled Study | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Not yet recruiting | Not applicable | 2026-10-09 | NCT07869342 | |
| A Study to Better Understand the Diagnosis and Treatment of Polycythaemia Vera | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, bone marrow disorder, bone marrow neoplasm, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Not yet recruiting | Not stated | 2026-10-09 | NCT07868081 | |
| A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016) | Hemic and Lymphatic Diseases, Hypersensitivity, Delayed, immune system disorder, interstitial lung disease, lung disorder, lymphatic system disorder, lymphoproliferative syndrome, pulmonary sarcoidosis, respiratory system disorder, sarcoidosis | Not yet recruiting | Phase 2 | 2026-10-09 | NCT07867938 | |
| Tight Control of Treatment Adherence and Efficacy by Telemedicine for an Improved Personalized Management of Patients With Hemophilia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder | Recruiting | Not applicable | 2026-10-09 | NCT07867834 | |
| Identification of New Biomarkers in Haemophilic Arthropathy Through Transcriptome Analysis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder | Recruiting | Not applicable | 2026-10-09 | NCT07867821 | |
| Feasibility and Efficiency Study for the Implementation of a New Screening Method for Patients With Acute Myeloid Leukemia, in Laboratory Practice | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, acute promyelocytic leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Not yet recruiting | Not applicable | 2026-10-09 | NCT07867704 | |
| Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Not yet recruiting | Phase 2 | 2026-10-09 | NCT07867626 | |
| Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Phase 2 | 2026-10-09 | NCT07796373 | |
| Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM | Blood Protein Disorders, DNA Virus Infections, Hemic and Lymphatic Diseases, Hypogammaglobulinemia, Infections, Skin Diseases, Viral, Skin and Connective Tissue Diseases, Tumor Virus Infections, agammaglobulinemia, common wart, hematologic disorder, human papilloma virus infection, immune system disorder, immunodeficiency disease, inborn error of immunity, lymphatic system disorder, lymphoproliferative syndrome, skin disorder, skin disorder caused by infection, viral infectious disease | Enrolling by invitation | Phase 1 / Phase 2 | 2026-10-09 | NCT07775313 | |
| A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07735533 | |
| Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders | Bacterial Infections and Mycoses, Borrelia infectious disease, Hemic and Lymphatic Diseases, Infections, Picornaviridae infectious disease, RNA Virus Infections, bacterial infectious disease, bone marrow disorder, foot and mouth disease, gram-negative bacterial infections, hematologic disorder, mosaic trisomy 8, myelodysplastic syndrome, non-human animal disease, relapsing fever, spirochaetales infections, tick-borne infectious disease, vector-borne disease, viral infectious disease | Recruiting | Not stated | 2026-10-09 | NCT07683104 | |
| Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 | 2026-10-09 | NCT07676877 | |
| D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-10-09 | NCT07624513 | |
| A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell myeloma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07612787 | |
| Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 | 2026-10-09 | NCT07572136 | |
| A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2026-10-09 | NCT07558915 | |
| Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Phase 2 | 2026-10-09 | NCT07524530 | |
| Tranexamic Acid for Bleeding Reduction During TURP Surgery | Genital Diseases, Hemic and Lymphatic Diseases, Male Urogenital Diseases, Urogenital Diseases, anemia, benign prostatic hyperplasia, hematologic disorder, male reproductive system disorder, prostate disorder | Recruiting | Phase 4 | 2026-10-09 | NCT07460518 | |
| Study of INCA036978 in Participants With Myeloproliferative Neoplasms | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, neoplasm, primary myelofibrosis, thrombocytosis disease | Recruiting | Phase 1 | 2026-10-09 | NCT07441694 | |
| A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) | Cytopenia, Evans syndrome, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 2 | 2026-10-09 | NCT07421167 | |
| Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma | Hemic and Lymphatic Diseases, Lymphadenopathy, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T-cell non-Hodgkin lymphoma, adult T-cell leukemia/lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, neoplasm | Recruiting | Phase 1 | 2026-10-09 | NCT07388563 | |
| A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis | Recruiting | Phase 3 | 2026-10-09 | NCT07357727 | |
| Study of BMS-986453 in Newly Diagnosed Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 1 | 2026-10-09 | NCT07333261 |